Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-AIO in r/r SLE
NCT06653556Phase 1Completed
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-AIO in systemic lupus erythematosus (SLE). Primary endpoints: Treatment-Emergent Adverse Events at 104 weeks, Dose-Limiting Toxicity at 30 days and 2 more. Started Jan 2025; status: completed.
02
Drugs
LCAR-AIO
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06653556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653556.